Abstract: This disclosure provides a method for treating glioma in a subject comprising administering to the subject an anti-Programmed Death-1 (PD-1) antibody. In some embodiments, this invention relates to methods for treating glioma in a subject comprising administering to the subject a combination of an anti-cancer agent which is an anti-Programmed Death-1 (PD-1) anti-body and another anti-cancer agent such as an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody.

Abstract: This disclosure provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.

Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.

Abstract: This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.

Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.

Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.

Abstract: Methods for evaluation of fish oil, oils, omega-3 fatty acid compositions, and dietary supplements containing omega-3 essential fatty acids and other fats are provided herein. The relative purity and/or concentration of oil-containing aliquots can be determined by cooling approximately equal volumes of two or more aliquots to a temperature near or below 0 degrees Celsius. When cooled, the most opaque aliquots are the least pure. The invention also provide a method for determining whether an omega-3 fatty acid supplement is greater than 90% pure, which includes cooling the supplement to less than 0 degrees Celsius and a determining that the supplement is 90% pure if its appearance is essentially unchanged from its appearance and room temperature.

Abstract: Methods for evaluation of fish oil, oils, omega-3 fatty acid compositions, and dietary supplements containing omega-3 essential fatty acids and other fats are provided herein. The relative purity and/or concentration of oil-containing aliquots can be determined by cooling approximately equal volumes of two or more aliquots to a temperature near or below 0 degrees Celsius. When cooled, the most opaque aliquots are the least pure. The invention also provide a method for determining whether an omega-3 fatty acid supplement is greater than 90% pure, which includes cooling the supplement to less than 0 degrees Celsius and a determining that the supplement is 90% pure if its appearance is essentially unchanged from its appearance and room temperature.

Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.

Abstract: Inventors have made the surprising discovery that glutamate modulating agents are useful for treating borderline personality disorder and self-injurious behavior. Methods of treating borderline personality and self-injurious behavior are provided herein by administering a glutamate modulating agent to a patient are included herein. The invention also includes combination methods of treatment in which a glutamate modulating agent is administered with one or more other CNS active agent. Packaged pharmaceutical compositions containing a glutamate modulating agent and one or more other CNS agent are provided by the invention as are and packaged pharmaceutical formulations containing a glutamate modulating agent and instructions for using the glutamate modulating agent for treating borderline personality disorder or self-mutilating behavior.